Cumberland Pharmaceuticals (CPIX) and SciClone Pharmaceuticals said Tuesday that China's National Medical Products Administration has approved Vibativ injection, a treatment for patients with hospital-acquired and ventilator-associated pneumonia.
The companies said the approval follows an agreement granting SciClone exclusive rights to register, promote, and distribute Vibativ in the country.
The two companies plan to launch the product in China later this year, they added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.